Lrrk2 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Full Name | Leucine Rich Repeat Kinase 2 |
|---|
| Chromosomal Location | 12q12 |
|---|
| NCBI Gene ID | 120892 |
|---|
| OMIM | 609007 |
|---|
| Ensembl ID | ENSG00000188906 |
|---|
| UniProt | Q5S007 |
|---|
| Associated Diseases | Parkinson's Disease |
|---|
LRRK2 (Leucine-Rich Repeat Kinase 2), located on chromosome 12q12, encodes a large (~2,527 amino acids) multi-domain protein with both kinase and GTPase activity[^1]. It is one of the most common genetic causes of Parkinson's disease (PD), with pathogenic mutations causing autosomal dominant PD with incomplete penetrance[^2]. LRRK2 is highly expressed in the brain, particularly in dopaminergic neurons of the substantia nigra pars compacta, and its dysfunction leads to progressive neurodegeneration through multiple interconnected pathways.
The LRRK2 gene encodes leucine-rich repeat kinase 2 (LRRK2), a complex multi-domain protein with both kinase and GTPase activity:
- Kinase activity: Phosphorylates itself and downstream substrates including tau, 14-3-3 proteins, and ribosomal proteins. The kinase domain is the primary therapeutic target for LRRK2 inhibitors[^3].
- GTPase activity: Regulated by ROC (Ras of complex proteins) domain, which functions as a molecular switch controlling LRRK2 signaling.
- Protein interactions: Associates with synaptic vesicles, mitochondria, and cytoskeletal proteins.
- Autophagy regulation: Modulates autophagy and lysosomal function, critical for protein quality control.
- Dopaminergic signaling: Influences dopamine receptor trafficking and signaling.
- Inflammation: Expressed in microglia; mutations may affect neuroinflammation.
LRRK2 is structurally complex with multiple functional domains: LRR (leucine-rich repeat), ROC (GTPase), COR (C-terminal of ROC), and kinase domains. The protein localizes to multiple cellular compartments including the cytoplasm, membrane fractions, mitochondria-associated membranes, and lysosomes.
¶ Protein Domains
| Domain |
Amino Acids |
Function |
| ARM repeat |
1-100 |
Protein-protein interactions |
| LRR |
100-500 |
Leucine-rich repeats, substrate recognition |
| ROC |
600-800 |
GTP/GDP binding, GTPase activity |
| COR |
800-1000 |
Dimerization, regulates ROC activity |
| Kinase |
1200-1500 |
ATP binding, phosphotransfer |
| WD40 |
2000-2300 |
Protein interactions |
- Inheritance: Autosomal dominant
- Prevalence: G2019S mutation accounts for ~5% familial PD and 1-2% sporadic PD worldwide; higher in certain populations (up to 40% in North African Arab populations)
- Mechanism: Over 100 pathogenic mutations identified; most are gain-of-function that increase kinase activity[^4]
| Mutation |
Domain |
Effect |
Frequency |
| G2019S |
Kinase |
Increased kinase activity |
Most common |
| R1441C/G/H |
ROC/GTPase |
Impaired GTPase activity |
Common |
| N1437H |
ROC |
Reduced GTPase activity |
Rare |
| A1442P |
ROC |
Altered GTP binding |
Rare |
| G2385R |
WD40 |
Risk factor |
Asian populations |
| R1628P |
WD40 |
Risk factor |
Asian populations |
- Enhanced kinase activity: G2019S and other kinase domain mutations increase autophosphorylation and substrate phosphorylation.
- Impaired protein clearance: LRRK2 dysfunction affects autophagy-lysosomal pathway.
- Mitochondrial dysfunction: Altered mitochondrial dynamics, quality control, and energy metabolism.
- Synaptic deficits: Impaired synaptic vesicle trafficking and dopamine release.
- Neuroinflammation: Microglial activation and inflammatory cytokine production.
- Axonal transport defects: Impaired microtubule-based transport.
- Incomplete: Age-dependent penetrance ranging from 30-80% by age 80 for G2019S carriers.
- Modifiers: Other genetic variants, environmental factors influence age of onset.
- Dementia with Lewy Bodies: LRRK2 mutations found in some DLB cases.
- Amyotrophic Lateral Sclerosis: Rare variants identified in ALS cohorts.
- Inflammatory Bowel Disease: LRRK2 is a risk gene for Crohn's disease.
- High expression: Brain (cortex, basal ganglia, cerebellum), kidney, lung, spleen.
- Cellular localization: Membrane-associated, cytoplasmic, mitochondrial-associated membranes.
- Regional specificity: High in substantia nigra pars compacta (dopaminergic neurons).
- Cell types: Neurons, microglia, astrocytes, oligodendrocytes.
- Allen Brain Atlas: High expression in cortical pyramidal neurons.
LRRK2 kinase inhibitors are the primary therapeutic approach:
- DNL151 (Denali): Phase 1/2 trials completed; brain-penetrant, selective LRRK2 inhibitor.
- DNL151 + BMS-986367: Combination approach in clinical trials.
- LL5418: Preclinical candidate with favorable brain penetration.
- Peripheral toxicity: LRRK2 inhibition may cause lung and kidney effects.
- Therapeutic window: Balancing CNS exposure with peripheral toxicity.
- Biomarker development: Need for target engagement biomarkers.
- AAV-LRRK2: Gene silencing approaches using RNA interference.
- CRISPR-Cas9: Allele-specific editing of pathogenic mutations.
- LRRK2 knockout: Mild phenotypes, subtle motor deficits with aging.
- LRRK2 G2019S knock-in: Progressive motor deficits, dopaminergic neuron loss, protein inclusions.
- Transgenic overexpression: Variable phenotypes depending on promoter.
- C. elegans: LRRK2 models show dopaminergic neuron degeneration.
- Drosophila: LRRK2 mutants display locomotor deficits and reduced lifespan.
- Paisán-Ruíz C, et al. (2004). "Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease." Neuron. PMID:15622517
- Zimprich A, et al. (2004). "Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology." Neuron. PMID:15622518
- Cookson MR. (2015). "LRRK2 and the autophagy-lysosome system." Mov Disord. PMID:26364128
- Schapansky J, et al. (2014). "Familial Parkinson's disease mutations drive LRRK2-mediated inhibition of microsomal autophagy." J Neurosci. PMID:25505339
- West AB, et al. (2005). "Parkinson disease-associated mutations in LRRK2 link enhanced GTPase signaling to neurotoxicity." Hum Mol Genet. PMID:15615773
- Alessi DR, et al. (2015). "LRRK2 kinase inhibition: a therapeutic strategy for Parkinson's disease?" Ann Neurol. PMID:26351916
- Jensen PH, et al. (2019). "LRRK2: from kinase to function." Brain. PMID:30698619
- Berger Z, et al. (2020). "LRRK2 and protein aggregation in Parkinson's disease." J Parkinsons Dis. PMID:32176669
The study of Lrrk2 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
-
- 1 Zimprich A, et al. (2004). Mutations in LRRK2 cause familial Parkinson disease. Nat Genet. PMID:15473508.
- 2 Cookson MR. (2010). The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat Rev Neurosci. PMID:20467445.
- 3 Alessi DR, et al. (2015). LRRK2 kinase inhibition: a therapeutic strategy for Parkinson's disease? Ann Neurol. PMID:26351916.
- 4 West AB, et al. (2005). Parkinson disease-associated mutations in LRRK2 link enhanced GTPase signaling to neurotoxicity. Hum Mol Genet. PMID:15615773.
- 5 Bonifati V. (2007). LRRK2 Parkinson disease. Clin Genet. PMID:18024353.
- 6 Paisan-Ruiz C, et al. (2010). LRRK2 function and dysfunction. FEBS J. PMID:20945528.
- 7 Jaleel M, et al. (2007). LRRK2: a phosphorylation hub. Cell. PMID:17635900.
- 8 Moore A, et al. (2020). LRRK2 inhibitors: a new class of Parkinson's disease therapeutics. Expert Opin Ther Pat. PMID:32176234.
-